How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Fosdenopterin for treating molybdenum cofactor deficiency type A

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about fosdenopterin

Marketing authorisation indication

2.1

Fosdenopterin (Nulibry, Sentynl Therapeutics) is indicated for 'the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A'.

Price

2.3

The list price of fosdenopterin is £1,205.51 per 9.5 mg vial (excluding VAT; company submission accessed September 2024). The list-price treatment cost per person for the first year is estimated to be £529,158. The list-price treatment cost per person for the fifth year is estimated to be £1,056,748. The costs take people's weight into account.

2.4

The company has a commercial arrangement, which would have applied if fosdenopterin had been recommended.